As diagnoses climb and innovation accelerates, major federal funding cuts are forcing a shift toward private biotech - and ...

A new wave of innovation is reshaping small-cap markets across sectors including oncology, functional energy beverages, ...

Stitch Fix reported quarterly losses of six cents per share, which beat the analyst consensus estimate of losses of 11 cents per share. Quarterly revenue came in at $325.02 million, beating the ...

Imunon, Inc. (NASDAQ:IMNN), a company operating in the biotechnology sector, is part of key market indexes such as the Top ...

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer of ...

US-based biotechnology company Imunon has reported positive results from its Phase II OVATION 2 trial of IMNN-001 for ovarian ...

Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, ...

These 10 Firms Crushed The Market Last Week. In this article, we are going to take a look at where Imunon, Inc. (NASDAQ:IMNN) ...

IMUNON, Inc. raises $3.25 million through the sale of shares and warrants, potentially totaling $9.75 million with full warrant exercise. IMUNON, Inc. has completed a private placement raising ...

LAWRENCEVILLE, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today closed on the previously ...

Imunon hit its highest levels in nearly three years Tuesday, fueled by its announcement to present Phase 2 OVATION 2 study immune biomarker data at the European Society for Medical Oncology ...

(NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that it has entered into definitive agreements for the issuance and sale of an ...